Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cervical cancer (specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, whether HPV-positive or HPV-negative) and whose treatment plan includes a combination of chemotherapy and radiation therapy followed by a specialised internal radiation treatment called brachytherapy.
- People whose cancer treatment plan requires radiation to cover the lymph node regions in the upper pelvis or upper pelvis and abdomen, within specific size limits (confirm with trial site).
- People whose cancer has not spread beyond the lymph nodes near the main abdominal artery, as confirmed by a CT or PET-CT scan.
- People aged 18 or older.
- People who are generally well or have only mild symptoms affecting daily activity, as measured by a standard medical scale called WHO performance status 0–1 (confirm with trial site).
- People whose kidneys, white blood cells, infection-fighting cells, and platelets are all functioning at adequate levels, based on blood tests (confirm with trial site).
- People who are able to attend all required treatment appointments and follow-up visits.
- People who have provided written consent to participate, in line with the requirements of the local ethics committee.
Who may not be able to join:
- People whose cervical cancer is of a rare type, such as small cell cancer or melanoma of the cervix.
- People who have had another cancer in the past that may still be active, as assessed by the study doctor — though exceptions may apply for cancers that were treated with the aim of a cure and have shown no signs of returning for at least 5 years, or for certain treated skin cancers with no current signs of disease.
- People with serious heart conditions, such as a recent heart attack, signs of heart failure, or a significant irregular heartbeat.
- People who have previously had radiation therapy to the pelvis or abdomen.
- People with a history of a primary immune system deficiency condition.
- People with a current or past diagnosis of an autoimmune or inflammatory condition, including inflammatory bowel conditions such as colitis or Crohn's disease.
- People who are currently taking medications that suppress the immune system.
- People for whom the chemotherapy drugs cisplatin or carboplatin are medically unsuitable.
- People for whom an MRI scan is medically unsuitable (confirm with trial site for specific contraindications).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stephanie M. de Boer, MD, PhD, Leiden University Medical Center
Phone: +31 71 529 7893
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dmean to the pelvic bones; Mean V15Gy to the bowel
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.